Amgen Inc. (NASDAQ:AMGN) Shares Bought by E&G Advisors LP

E&G Advisors LP raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,472 shares of the medical research company’s stock after buying an additional 200 shares during the period. E&G Advisors LP’s holdings in Amgen were worth $797,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of AMGN. Security Financial Services INC. grew its position in Amgen by 5.1% in the 1st quarter. Security Financial Services INC. now owns 968 shares of the medical research company’s stock valued at $275,000 after acquiring an additional 47 shares in the last quarter. Northwest Investment Counselors LLC grew its holdings in shares of Amgen by 7.5% in the first quarter. Northwest Investment Counselors LLC now owns 3,603 shares of the medical research company’s stock valued at $1,024,000 after purchasing an additional 250 shares in the last quarter. CHICAGO TRUST Co NA increased its stake in Amgen by 6.4% during the 1st quarter. CHICAGO TRUST Co NA now owns 8,487 shares of the medical research company’s stock worth $2,413,000 after buying an additional 513 shares during the period. AdvisorNet Financial Inc lifted its holdings in Amgen by 5.7% during the 1st quarter. AdvisorNet Financial Inc now owns 2,206 shares of the medical research company’s stock worth $627,000 after buying an additional 119 shares in the last quarter. Finally, Peak Financial Advisors LLC purchased a new position in Amgen in the 1st quarter valued at approximately $2,827,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Amgen stock opened at $321.66 on Friday. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The stock has a fifty day moving average of $326.07 and a two-hundred day moving average of $312.15. The company has a market capitalization of $172.55 billion, a price-to-earnings ratio of 45.95, a PEG ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm’s revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the business posted $5.00 EPS. On average, analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.80%. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Oppenheimer reiterated an “outperform” rating and issued a $380.00 price objective on shares of Amgen in a research note on Wednesday, August 7th. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. Cantor Fitzgerald initiated coverage on Amgen in a research report on Friday, September 27th. They set an “overweight” rating and a $405.00 price objective for the company. Bank of America raised their target price on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Finally, Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $329.48.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.